Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of December 2021, with the report signed on December 3, 2021. The Company is a foreign private issuer based in Caesarea, Israel, focusing on medical devices.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a regulatory update regarding regulatory submissions rather than a financial statement.
Material Changes
The primary material event reported is a regulatory submission made on November 24, 2021. Icecure submitted a pre-submission package to the U.S. Food and Drug Administration (FDA) proposing an intended use for early-stage breast cancer and high-risk surgery for its IceCure family of systems. The Company suggested a De Novo classification for these indications.
Guidance, Outlook, and Management Commentary
- Regulatory Strategy: Leveraging its previously granted Breakthrough Device Designation for the ProSense system, the Company requested a "sprint discussion" under FDA procedures as part of the pre-submission package.
- Outlook: The filing indicates active engagement with the FDA to expand the approved indications for its core product family.
- Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of the regulatory approval process.
Investor Verification Checklist
- Verify the status and outcome of the FDA "sprint discussion" requested in the pre-submission package.
- Confirm the timeline for the FDA's response regarding the proposed De Novo classification for early-stage breast cancer.
- Review subsequent filings for any updates on the Breakthrough Device Designation status for the ProSense system.